[go: up one dir, main page]

DE69636122D1 - Verfahren zur einführung von genen in zielzellen mit hilfe von retroviren - Google Patents

Verfahren zur einführung von genen in zielzellen mit hilfe von retroviren

Info

Publication number
DE69636122D1
DE69636122D1 DE69636122T DE69636122T DE69636122D1 DE 69636122 D1 DE69636122 D1 DE 69636122D1 DE 69636122 T DE69636122 T DE 69636122T DE 69636122 T DE69636122 T DE 69636122T DE 69636122 D1 DE69636122 D1 DE 69636122D1
Authority
DE
Germany
Prior art keywords
retrovirus
target cells
help
effective amount
functional material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636122T
Other languages
English (en)
Other versions
DE69636122T2 (de
Inventor
Kiyozo Asada
Takashi Uemori
Takashi Ueno
Nobuto Koyama
Kimikazu Hashino
Ikunoshiu Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Bio Inc
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Application granted granted Critical
Publication of DE69636122D1 publication Critical patent/DE69636122D1/de
Publication of DE69636122T2 publication Critical patent/DE69636122T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C12N9/1088—Glutathione transferase (2.5.1.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69636122T 1995-11-13 1996-11-07 Verfahren zum gentransfer in zielzellen mit einem retrovirus Expired - Lifetime DE69636122T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP29438295 1995-11-13
JP29438295 1995-11-13
JP5184796 1996-03-08
JP5184796 1996-03-08
PCT/JP1996/003254 WO1997018318A1 (en) 1995-11-13 1996-11-07 Method for gene introduction into target cells by retrovirus

Publications (2)

Publication Number Publication Date
DE69636122D1 true DE69636122D1 (de) 2006-06-14
DE69636122T2 DE69636122T2 (de) 2006-12-07

Family

ID=26392431

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636122T Expired - Lifetime DE69636122T2 (de) 1995-11-13 1996-11-07 Verfahren zum gentransfer in zielzellen mit einem retrovirus

Country Status (13)

Country Link
US (5) US6472204B1 (de)
EP (1) EP0870839B1 (de)
JP (1) JP3343357B2 (de)
KR (2) KR100395420B1 (de)
CN (1) CN100390290C (de)
AT (1) ATE325884T1 (de)
AU (1) AU709831B2 (de)
CA (1) CA2235629A1 (de)
DE (1) DE69636122T2 (de)
EA (3) EA004928B1 (de)
ES (1) ES2259182T3 (de)
MX (1) MX9803706A (de)
WO (1) WO1997018318A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083979B1 (en) 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
AU731767B2 (en) 1995-06-15 2001-04-05 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
DE69636124T2 (de) * 1995-09-29 2006-12-21 Indiana University Research And Technology Corp., Bloomington Verfahren zum verbesserten virusvermittelten dns-transfer unter verwendung von molekülen mit virus- und zellbindenden domänen
TWI239352B (en) * 1997-07-23 2005-09-11 Takara Bio Inc Gene transfer method with the use of serum-free medium
US6316692B1 (en) * 1997-11-14 2001-11-13 Cedars Sinai Medical Center Transfection, storage and transfer of male germ cells for generation of transgenic species and genetic therapies
US6787359B1 (en) * 1998-07-01 2004-09-07 Takara Shuzo Co., Ltd. Gene transfer methods
EP1124975A1 (de) * 1998-10-31 2001-08-22 University Of Medicine And Dentistry Of New Jersey Myeloid-vorläuferzelle für die verwendung bei der gentherapie und für die modulation von immunantworten
AU2944100A (en) * 1999-03-23 2000-10-09 Takara Shuzo Co., Ltd. Gene therapeutics
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US8236561B2 (en) * 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) * 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
AU5958000A (en) * 1999-07-08 2001-01-30 Connie Jean Eaves Method to improve viral infection
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
AU2001285263A1 (en) 2000-08-25 2002-03-13 The General Hospital Corporation Selective precipitation of viruses
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
DK1407787T3 (da) * 2001-06-20 2009-06-02 Dainippon Sumitomo Pharma Co Fremgangsmåde til fremme af nukleinsyreoverförsel
JP2005052001A (ja) * 2001-07-05 2005-03-03 Takara Bio Inc 遺伝子治療剤
TW200718784A (en) 2001-08-15 2007-05-16 Takara Bio Inc Method of extended culture for antigen-specific cytotoxic T lumphocytes
PT1465987E (pt) * 2001-12-07 2008-04-15 Crucell Holland Bv Produção de vírus, isolados virais e vacinas
AU2003221073B2 (en) * 2002-03-25 2008-08-21 Takara Bio Inc. Process for producing cytotoxic lymphocyte
US20100143442A1 (en) 2003-02-05 2010-06-10 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
US20040219099A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Method for the treatment of tumors
US20040220085A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Compositions for nucleic acid delivery
JP4865539B2 (ja) 2003-05-09 2012-02-01 クルセル ホランド ベー ヴェー Ｅ１不死化細胞の培養物及び該培養物を培養して該培養物から得られる産物の収量を増加させる方法
DK1626992T3 (da) * 2003-05-23 2010-09-20 Crucell Holland Bv Produktion af rekombinant IgM i PER.C6-celler
FR2857598A1 (fr) * 2003-07-18 2005-01-21 Inst Nat Sante Rech Med Composes anti-angiogeniques, composition pharmaceutique les comprenant, et leur utilisation
KR20060039940A (ko) 2003-08-22 2006-05-09 다카라 바이오 가부시키가이샤 세포 상해성 림프구의 제조 방법
GB0410130D0 (en) * 2004-05-06 2004-06-09 Molmed Spa Cell preparation
KR101086822B1 (ko) * 2004-09-29 2011-11-25 다카라 바이오 가부시키가이샤 레트로바이러스 벡터 생산용 세포
JPWO2006082958A1 (ja) * 2005-02-07 2008-06-26 タカラバイオ株式会社 レトロウイルスの保存方法
USD543589S1 (en) * 2005-04-28 2007-05-29 Michael Henley Tag
WO2006134871A1 (ja) 2005-06-15 2006-12-21 Takara Bio Inc. 脂肪細胞あるいは前駆脂肪細胞への遺伝子導入方法
CA2616863A1 (en) * 2005-07-29 2007-02-01 Australian Stem Cell Centre Limited Compositions and methods for growth of pluripotent cells
JP5122957B2 (ja) 2005-08-16 2013-01-16 タカラバイオ株式会社 免疫不全ウイルス感染症の治療または予防のための核酸
WO2007020880A1 (ja) 2005-08-17 2007-02-22 Takara Bio Inc. リンパ球の製造方法
JP4741906B2 (ja) * 2005-08-31 2011-08-10 タカラバイオ株式会社 リンパ球の製造方法
EA016168B1 (ru) 2005-09-30 2012-02-28 Такара Био Инк. Способ получения т-клеточной популяции и ее применение
KR20090024782A (ko) * 2006-06-09 2009-03-09 다카라 바이오 가부시키가이샤 림프구의 제조 방법
EP2138580B1 (de) 2007-04-20 2013-03-20 Takara Bio, Inc. Vektor für gentherapie
EP2267118A4 (de) 2008-03-27 2013-08-28 Takara Bio Inc Verfahren zur herstellung einer transfizierten zelle
CN102144027B (zh) 2008-07-07 2016-04-06 宝生物工程株式会社 生产多能干细胞的方法
WO2010080032A2 (en) * 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
JPWO2011024791A1 (ja) 2009-08-25 2013-01-31 タカラバイオ株式会社 レチノイン酸存在下でのｔ細胞集団の製造方法
WO2011030851A1 (ja) 2009-09-11 2011-03-17 タカラバイオ株式会社 ナチュラルキラー細胞の製造方法
ES2619938T3 (es) * 2009-11-30 2017-06-27 Factor Therapeutics Limited Quimeras de fibronectina: factor de crecimiento
US8841126B2 (en) 2010-06-30 2014-09-23 Takara Bio Inc. Method for gene transfer
US9228206B2 (en) 2010-06-30 2016-01-05 Takara Bio Inc. Method for gene transfer
US9861681B2 (en) 2013-04-18 2018-01-09 The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases Therapeutic compositions for neutralizing type I interferons, and methods of use
US11248238B2 (en) 2015-10-22 2022-02-15 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
KR20190033568A (ko) 2016-07-29 2019-03-29 다카라 바이오 가부시키가이샤 줄기세포의 제조에 사용되는 피브로넥틴 프래그먼트
WO2018053463A1 (en) 2016-09-19 2018-03-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells for genetic engineering of immune cells
CN108103045B (zh) * 2016-11-25 2022-10-04 丰益(上海)生物技术研发中心有限公司 脂肪酶及其应用
US12077590B2 (en) * 2017-02-22 2024-09-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
KR102692944B1 (ko) 2017-02-22 2024-08-07 루머스 리미티드 광 가이드 광학 어셈블리
KR20200112868A (ko) 2018-01-25 2020-10-05 다카라 바이오 가부시키가이샤 림프구의 제조방법
CA3123518C (en) 2019-01-24 2023-07-04 Lumus Ltd. Optical systems including loe with three stage expansion
CN114901793A (zh) * 2019-12-30 2022-08-12 美国圣戈班性能塑料公司 用于细胞转导的容器和方法
CN113444167B (zh) * 2021-07-15 2022-09-30 陕西巨子生物技术有限公司 重组人胶原蛋白多肽及其应用
CN114634984A (zh) * 2022-02-02 2022-06-17 复旦大学 一种脑胶质瘤生物标记物mlkl基因及其应用
WO2023213969A1 (en) * 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
CN114965839A (zh) * 2022-05-11 2022-08-30 朗肽生物制药股份有限公司 人碱性成纤维细胞生长因子的肽图分析方法
WO2024108221A1 (en) * 2022-11-18 2024-05-23 Saint-Gobain Performance Plastics Corporation Aptamers, containers and methods for cell transduction
CN117603343B (zh) * 2024-01-19 2024-04-26 四川大学 阻断bFGF的胶原来源天然短肽及应用
CN117645664A (zh) * 2024-01-29 2024-03-05 英特菲尔(成都)生物制品有限责任公司 重组人纤连蛋白标准品及其制备方法、鉴定方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
US5026839A (en) 1985-12-17 1991-06-25 Synergen, Inc DNA encoding a basic fibroblast growth factor
US4994559A (en) 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
JP2770926B2 (ja) * 1985-12-17 1998-07-02 サイナーゲン インコーポレーテッド 毛管内皮細胞プロテアーゼ合成、ｄｎａ合成および遊走を促進することの出来るヒト胎盤血管形成誘導因子
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5492890A (en) 1990-12-03 1996-02-20 The Scripps Research Institute Polypeptides for promoting cell attachment
DE4110409C2 (de) * 1991-03-29 1999-05-27 Boehringer Ingelheim Int Neue Protein-Polykation-Konjugate
JP2829405B2 (ja) * 1991-10-14 1998-11-25 寳酒造株式会社 機能性ポリペプチド
SE503225C2 (sv) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
CH685803A5 (fr) * 1992-06-09 1995-10-13 Francis Verdan Bâton d'alun fixé dans un étui.
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5686278A (en) * 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
JPH1029952A (ja) 1996-07-16 1998-02-03 Takara Shuzo Co Ltd ヒト免疫不全ウイルス感染の制御用組成物および制御方法

Also Published As

Publication number Publication date
EA200200837A1 (ru) 2002-12-26
AU7505896A (en) 1997-06-05
EA199800369A1 (ru) 1998-12-24
US20060030046A1 (en) 2006-02-09
US6949623B2 (en) 2005-09-27
EP0870839B1 (de) 2006-05-10
DE69636122T2 (de) 2006-12-07
US6426042B1 (en) 2002-07-30
EA003204B1 (ru) 2003-02-27
JP3343357B2 (ja) 2002-11-11
CN100390290C (zh) 2008-05-28
CA2235629A1 (en) 1997-05-22
AU709831B2 (en) 1999-09-09
CN1207774A (zh) 1999-02-10
KR100395420B1 (ko) 2003-08-21
US20030087437A1 (en) 2003-05-08
EA200001110A1 (ru) 2001-06-25
ATE325884T1 (de) 2006-06-15
EP0870839A1 (de) 1998-10-14
EA003195B1 (ru) 2003-02-27
EP0870839A4 (de) 2000-01-19
WO1997018318A1 (en) 1997-05-22
EA004928B1 (ru) 2004-10-28
KR100353115B1 (ko) 2003-01-06
US7790849B2 (en) 2010-09-07
KR19990067446A (ko) 1999-08-16
MX9803706A (es) 1998-09-30
US20090209730A1 (en) 2009-08-20
US7446170B2 (en) 2008-11-04
ES2259182T3 (es) 2006-09-16
US6472204B1 (en) 2002-10-29

Similar Documents

Publication Publication Date Title
DE69636122D1 (de) Verfahren zur einführung von genen in zielzellen mit hilfe von retroviren
ATE345682T1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
AU2161501A (en) Immobilized single domain antigen-binding molecules
DE69706187D1 (de) Zusammensetzungen und verfahren zur immobilisierung von nukleinsäure auf festträgern
ATE414171T1 (de) Verfahren zur immobilisierung von oligonukleotiden auf festem trägermaterial
FI971611L (fi) DNA-polymeraaseja joilla on modifioitu nukleotidisitoutumiskohta DNA-sekvensointia varten
AU2894289A (en) Domain-modified constant region antibodies
DE3673501D1 (de) Mittel und verfahren zur funktionalisierung von nukleinsaeuren.
WO1999016907A3 (en) Reagent and method for attaching target molecules to a surface
DE69637579D1 (de) Methode zur Amplifizierung von Nukleinsäure und entsprechende Regenzien dafür
DE69825002D1 (de) Verfahren zur Verbesserung der Stabilität und/oder Haltbarkeit von verschiedenen Substraten
DE69809561D1 (de) Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod
DE69024447D1 (de) Induzierer einer tumorlysierenden Zelle, Verfahren und Gerät zur Induzierung tumorlysierender Zellen
ATE135745T1 (de) Immobilisierung von organischen makromolekülen oder biopolymeren in einer polymermembran
ATE70916T1 (de) Mit ueberzuegen versehene formkoerper zur bindung von bioaffinen substanzen.
BR9712575A (pt) Processo para restaurar em células que apresentam uma proteìna p53 que sofreu mutação , uma atividade de transactivação p53-dependente, utilizações de um anticorpo de cadeia simples capaz de ligar especificamente uma proteìna p53 que sofreu mutação, e de um ácido nucleico codificante, molécula 11d3 ou uma variante, ácido nucleico e composição
ATE247710T1 (de) Genexpression von utrophin
DE69221826D1 (de) Aufgetragene Mikrokugeln
DE69514415D1 (de) Verfahren zur Herstellung von Dioxazinverbindungen,damit gefärbte Materialien und Dioxazinverbindungen mit plattenartiger Kristallform.
ES8802556A1 (es) Procedimiento para controlar el desprendimiento de microorganismos adheridos a superficies
ATE389727T1 (de) Modulatoren der expression von morphogenen und deren identifizierungsverfahren
DE59700281D1 (de) Verfahren zur Herstellung von Aminoessigsäuren mit alpha-ständigem tertiären Kohlenwasserstoffrest oder deren Nitrilen
DE69704885D1 (de) Zusammensetzung und Verfahren zur Leimung von flächigen Strukturen
RU2000106030A (ru) Способ воздействия на связывание p53 с геном-мишенью
ATA33696A (de) Verfahren zum immobilisieren von schadstoffen und festkörper mit immobilisierten schadstoffen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition